Cargando…

Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study

INTRODUCTION: Orlistat is an inhibitor of pancreatic lipase and is used as an anti-obesity drug in many countries. However, there are no data available regarding the effects of orlistat on visceral fat accumulation in Japanese subjects. Therefore, this comparative, placebo-controlled, double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirai, Kohji, Fujita, Toru, Tanaka, Michitaka, Fujii, Yuka, Shimomasuda, Masatsugu, Sakai, Soichi, Samukawa, Yoshishige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318260/ https://www.ncbi.nlm.nih.gov/pubmed/30535651 http://dx.doi.org/10.1007/s12325-018-0835-5

Ejemplares similares

Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study
por: Shirai, Kohji, et al.
Publicado: (2018)

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2014)

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
por: Sasaki, Takashi, et al.
Publicado: (2015)

PPARγ as a sensor of lipase activity and a target for the lipase inhibitor orlistat
por: Martin, Harry, et al.
Publicado: (2013)

Selection of orlistat as a potential inhibitor for lipase from Candida species
por: Khedidja, Benarous, et al.
Publicado: (2011)

The Use of Orlistat in an Adult with Lipoprotein Lipase Deficiency: A Case Report
por: Jarrett, Zachary S., et al.
Publicado: (2021)

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
por: Kumagai, Yuji, et al.
Publicado: (2015)

Direct Measurement of Lipase Inhibition by Orlistat Using a Dissolution Linked In Vitro Assay
por: Lewis, Daniel R, et al.
Publicado: (2012)

Crystal structure of pathogenic Staphylococcus aureus lipase complex with the anti-obesity drug orlistat
por: Kitadokoro, Kengo, et al.
Publicado: (2020)

Absence of Drug–Drug Interactions Between Luseogliflozin, a Sodium–Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males
por: Sasaki, Takashi, et al.
Publicado: (2015)

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2016)

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
por: Samukawa, Yoshishige, et al.
Publicado: (2016)

Comparision of Efficacy and Safety of Orlistat vs Placebo in Obese Patients in Pakistan
por: Syed, Asghar Hussain, et al.
Publicado: (2020)

Effect of orlistat alone or in combination with Garcinia cambogia on visceral adiposity index in obese patients
por: Al-kuraishy, Hayder M., et al.
Publicado: (2016)

Comparison of Efficacy of Fermented Garlic and Orlistat (Lipase Inhibitor) in Obesity Management Using an Experimental Rodent Model
por: Javed, Mavra, et al.
Publicado: (2023)

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
por: Chino, Yukihiro, et al.
Publicado: (2014)

Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups
por: Gunay, Yasemin Emur, et al.
Publicado: (2023)

Refsum's Disease—Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder
por: Perera, Nimalie J., et al.
Publicado: (2011)

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
por: Samukawa, Yoshishige, et al.
Publicado: (2018)

Obesity management: Update on orlistat
por: Drew, Belinda S, et al.
Publicado: (2007)

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus
por: Seino, Yutaka, et al.
Publicado: (2015)

Anti-Lipase Potential of the Organic and Aqueous Extracts of Ten Traditional Edible and Medicinal Plants in Palestine; a Comparison Study with Orlistat
por: Jaradat, Nidal, et al.
Publicado: (2017)

Orlistat in the prevention of diabetes in the obese patient
por: Mancini, Marcio C, et al.
Publicado: (2008)

Macrocytic Anemia and Thrombocytopenia Induced by Orlistat
por: Palacios-Martinez, David, et al.
Publicado: (2013)

Acute oxalate nephropathy associated with orlistat
por: Humayun, Youshay, et al.
Publicado: (2016)

Evaluation of efficacy and safety of orlistat in obese patients
por: Jain, Suyog S., et al.
Publicado: (2011)

The Effect of Orlistat on Sterol Metabolism in Obese Patients
por: Kwon, Yu-Jin, et al.
Publicado: (2022)

High Sensitivity of Giardia duodenalis to Tetrahydrolipstatin (Orlistat) In Vitro
por: Hahn, Juliane, et al.
Publicado: (2013)

Orlistat-Induced Gut Microbiota Modification in Obese Mice
por: Ke, Jing, et al.
Publicado: (2020)

Inhibition of CpLIP2 Lipase Hydrolytic Activity by Four Flavonols (Galangin, Kaempferol, Quercetin, Myricetin) Compared to Orlistat and Their Binding Mechanisms Studied by Quenching of Fluorescence
por: Nasri, Ruba, et al.
Publicado: (2019)

Effects of a novel weight‐loss combination product containing orlistat and acarbose on obesity: A randomized, placebo‐controlled trial
por: Holmbäck, Ulf, et al.
Publicado: (2022)

Clinical and economic considerations of antiobesity treatment: a review of orlistat
por: Zohrabian, Armineh
Publicado: (2010)

Taking Orlistat: Predicting Weight Loss over 6 Months
por: Hollywood, Amelia, et al.
Publicado: (2011)

Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase
por: Fako, Valerie E., et al.
Publicado: (2014)

An Unexpected Result of Obesity Treatment: Orlistat-Related Acute Pancreatitis
por: Kose, Murat, et al.
Publicado: (2015)

The Application of Quantitative (1)H-NMR for the Determination of Orlistat in Tablets
por: Sun, Shanshan, et al.
Publicado: (2017)

The effect of orlistat and weight loss diet on plasma ghrelin and obestatin
por: Pamuk, Baris, et al.
Publicado: (2018)

Risk of colorectal cancer after initiation of orlistat: matched cohort study
por: Hong, Jin-Liern, et al.
Publicado: (2013)

Orlistat-loaded solid SNEDDS for the enhanced solubility, dissolution, and in vivo performance
por: Kim, Dae Hun, et al.
Publicado: (2018)

Orlistat Induces Ferroptosis in Pancreatic Neuroendocrine Tumors by Inactivating the MAPK Pathway
por: Ye, Mujie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ga9fahlqq20f81fd8vk7ps9al1